Form 4: Ventyx Director's Options Cancelled in Eli Lilly Merger

Ventyx Biosciences Director Allison Hulme's stock options were cancelled as part of the company's acquisition by Eli Lilly and Company, with some converted to cash and others for no consideration.

Summary

• Allison Hulme, a Director of Ventyx Biosciences, Inc., reported changes in her beneficial ownership of derivative securities (stock options).
• These changes occurred on March 4, 2026, as a direct result of the merger of Ventyx Biosciences, Inc. with RYLS Merger Corporation, a wholly-owned subsidiary of Eli Lilly and Company.
• Ventyx Biosciences, Inc. has become a wholly-owned subsidiary of Eli Lilly and Company following the merger.
• Stock options with an exercise price less than or equal to $14.00 per share were automatically cancelled and converted into a cash payment.
• Stock options that were fully vested and had an exercise price greater than $14.00 per share were automatically cancelled for no consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Ventyx shareholders and in-the-money option holders, as it provides a definitive liquidity event and a premium for their shares. The cancellation of out-of-the-money options is a standard, albeit negative, outcome for those specific holdings.

Positives

• The merger with Eli Lilly and Company provides a definitive liquidity event for Ventyx Biosciences shareholders and in-the-money option holders.
• Director Allison Hulme received cash for her in-the-money stock options, which covered 93,000 shares (33,000, 40,000, and 20,000 shares at exercise prices of $3.285, $2.25, and $1.97 respectively).

Negatives

• Director Allison Hulme's out-of-the-money stock options, totaling 36,364 shares (15,937 and 20,427 shares at exercise prices of $34.83 and $34.16 respectively), were cancelled for no consideration, representing a loss of potential future value.
• Ventyx Biosciences, Inc. has ceased to be an independent publicly traded entity.

Future Outlook

The filing reports a completed merger, and as Ventyx Biosciences is now a wholly-owned subsidiary of Eli Lilly and Company, its future outlook as an independent entity is no longer applicable. Its operations and strategic direction will be determined by Eli Lilly.

Industry Context

StockSavvy.ai notes that the acquisition of Ventyx Biosciences by Eli Lilly and Company aligns with a broader industry trend where major pharmaceutical companies acquire smaller biotech firms to enhance their drug pipelines and expand into new therapeutic areas. This transaction specifically strengthens Eli Lilly's portfolio through Ventyx's assets.

Comparison to Industry Standards

• The acquisition price of $14.00 per share for Ventyx Biosciences common stock should be evaluated against recent M&A transactions in the biotechnology sector, particularly those involving companies with similar pipeline stages or therapeutic focuses. For instance, comparisons could be drawn with acquisitions like Pfizer's purchase of Arena Pharmaceuticals for $6.7 billion or Bristol Myers Squibb's acquisition of MyoKardia for $13.1 billion, to assess the valuation multiples (e.g., enterprise value to peak sales, or per-asset valuation) in the context of Ventyx's specific drug candidates.
• The treatment of stock options, where in-the-money options are cashed out and out-of-the-money options are cancelled for no consideration, is a standard and widely accepted practice in corporate mergers and acquisitions.

Corporate Governance

Stakeholder Impact

• Shareholders of Ventyx Biosciences received $14.00 per share in cash for their common stock as part of the merger.
• Option holders with in-the-money options received cash for the intrinsic value of their holdings, while those with out-of-the-money options had them cancelled for no consideration.
• Employees of Ventyx Biosciences are now part of Eli Lilly and Company, which may lead to changes in compensation, benefits, and corporate culture.
• Customers and suppliers of Ventyx Biosciences may experience changes in their relationships or contractual agreements as the company integrates into Eli Lilly's operations.

Next Steps

• Ventyx Biosciences will continue its operations as a wholly-owned subsidiary of Eli Lilly and Company.
• Eli Lilly will proceed with the integration of Ventyx's assets, personnel, and operations into its broader corporate structure.

Key Dates

Recommendation

Ventyx Biosciences, Inc. has been acquired by Eli Lilly and Company and is now a wholly-owned subsidiary. Its common stock is no longer publicly traded, rendering a 'hold' recommendation as the most appropriate action for former shareholders who have already received their cash consideration.

Keywords

Ventyx Biosciences, Eli Lilly, Merger, Acquisition, Form 4, Stock Options, Insider Transaction, VTYX